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Abstract
Introduction Most previous studies have focused on evaluating
the association between circulating insulin-like growth factor
binding protein 3 (IGFBP-3) levels and breast cancer risk.
Emerging evidence over the past few years suggests that
IGFBP-3 may act directly on mammary epithelial cells.
Methods To understand the role of IGFBP-3 in breast
tumorigenesis, we investigated IGFBP3  mRNA expression
levels in benign and malignant breast tumors and their adjacent
normal tissues using real-time quantitative PCR.
Results Cancer tissues had significantly lower IGFBP3
expression than benign tumor tissues (p  < 0.001). IGFBP3
expressions in both tumor and adjacent tissues were higher in
patients who had proliferative benign tumors than in those who
had non-proliferative benign tumors. Among patients with
benign breast disease, IGFBP3 expression in the tumor was
significantly higher than that in their adjacent normal tissue.
There were no apparent associations of IGFBP3 expression in
cancer tissues with either overall survival or disease-free survival
in a cohort of 521 patients with breast cancer.
Conclusion Our findings suggest that the expression level of
IGFBP3  in breast tissues may be involved in breast
tumorigenesis.
Introduction
The insulin-like growth factor (IGF) system is important in reg-
ulating cell proliferation, differentiation, apoptosis, and trans-
formation [1]. In vitro studies have consistently shown that
members of the IGF family not only regulate the growth of var-
ious cancer cells but also interact with other cancer-related
molecules [1,2]. Insulin-like growth factor binding protein 3
(IGFBP-3) is the most abundant IGFBP in circulation [3].
IGFBPs can either suppress or enhance the action of IGFs.
Because the affinity of IGFBPs for IGFs is the same as or
greater than that of the IGF-I receptors, the presence of
IGFBPs could inhibit IGF activity by decreasing levels of free
IGFs available to activate the receptor [2,3]. However, the
binding of IGFBPs to IGFs protects IGFs from proteolytic deg-
radation, thus enhancing the action of IGFs by increasing their
bioavailability in local tissues [3]. In meta-analyses of the asso-
ciation between the blood concentration of IGFBP-3 and
breast cancer risk, high blood levels of IGFBP-3 were associ-
ated with an increased risk of premenopausal breast cancer
but not with that of postmenopausal breast cancer [4,5]. How-
ever, a recent nested case-control study in the European Pro-
spective Investigation into Cancer and Nutrition (EPIC)
showed an increased risk for breast cancer with high circulat-
ing IGFBP-3 after 50 years of age [6]. No association was
observed in younger women [6].
IGFBP-3 has been shown to induce apoptosis of breast can-
cer cells and inhibit breast cell growth in IGF-independent
ways [3,7,8]. Many tissues express IGFBP3 [3], and breast
tissue also expresses it [9-11]. Most previous studies have
focused on evaluating circulating IGFBP-3, and almost none
have systematically investigated the level of this important
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protein in breast tissues from patients with invasive cancer and
benign breast diseases (BBDs). In the present study we eval-
uated the expression level of the IGFBP3 gene in breast tis-
sues from patients with breast cancer or BBD, and
investigated potential associations between IGFBP3 mRNA
expression levels and the clinicopathologic features of the
tumors and breast cancer survival.
Materials and methods
Study subjects and tissue samples
Included in this study was a subset of patients who partici-
pated in the Shanghai Breast Cancer Study [12]. These
patients were diagnosed with breast cancer or BBD between
1996 and 1998. Study patients were recruited through a rapid
case ascertainment system established through a network of
major hospitals that treat more than 80% of breast cancer
cases in urban Shanghai. A total of 1,602 women who were
diagnosed with a primary breast cancer were identified. Of
these, 1,459 (91.1%) participated in the Shanghai Breast
Cancer Study. During the operation, tissue samples were
obtained from the tumor and another section (if available) from
the distal edge of the resection. These samples were snap-fro-
zen in liquid nitrogen as soon as possible, typically within 10
minutes. Samples were stored at -70°C until the relevant
assays were performed.
All patients were interviewed at the time of recruitment. A
structured questionnaire was used in this study to collect infor-
mation on demographic factors, menstrual and reproductive
history, hormone use, previous disease history, family history of
cancer, physical activity, tobacco and alcohol use, and usual
dietary habits. All participants were measured for current
weight, circumferences of the waist and hips, and sitting and
standing heights. Medical charts were reviewed using a stand-
ard protocol to obtain information on cancer treatment, clinical
stages and cancer characteristics, such as estrogen and pro-
gesterone receptor status. Two senior pathologists reviewed
pathology slides to confirm the diagnosis for breast cancer or
BBD. BBDs were classified on the basis of the published cri-
teria developed by Page and colleagues [13].
All of the patients with breast cancer of the main study were
followed until July 2005 by a combination of in-person or tele-
phone contacts and record linkage to the death certificates
kept by the Shanghai Vital Statistics Unit [14,15]. In all, 89.2%
of patients successfully completed the follow-up interview
either in person or by telephone. For those who could not be
contacted in person or by telephone, linkage to the death cer-
tificate data was completed to obtain information on the date
and cause of death. Subjects who had no match in the death
registry were assumed to be alive on 30 December 2004, 6
months before the linkage, to allow for a possible delay of entry
of the death certificates into the registry.
Laboratory methods
Total RNA was extracted from tissue specimens by homogeni-
zation in TRIzol solution (Gibco BRL, Carlsbad, CA, USA),
phase separation, precipitation, and washing in accordance
with the manufacturer's instructions. The quality and quantity
of RNA were measured by spectrophotometric analysis. RNA
was reverse-transcribed in a final volume of 15 μl containing
0.15 μg RNA and 1 × RT-PCR buffer, 5.5 mM MgCl2, dNTPs
(each at 500 μM), 2.5 μM random hexamers, 0.4 U/μl RNase
inhibitor, and 3.125 U/μl MultiScribe reverse transcriptase
(Applied Biosystems, Foster, CA, USA). The mixture was incu-
bated at 25°C for 10 minutes, at 37°C for 120 minutes and
95°C for 5 minutes.
The primers and probes used for the IGFBP3 (Hs00426287)
and β-actin (Hs99999903) genes were obtained from Applied
Biosystems. Quantitative real-time PCR was performed with a
384-well optic plate on an ABI PRISM® 7900HT Sequence
Detection System (Applied Biosystems). A total reaction vol-
ume of 5 μl containing 2.2 μl of cDNA template (1:10 dilution),
1 × TaqMan Universal PCR Master Mix (without uracil-N-glyc-
osylase), and 1 × Gene Expression Assay Mix including the
primers, and marked probes from Applied Biosystems Assays-
on-Demand services. The thermal cycling conditions were as
follows: 95°C for 10 minutes to activate AmpliTaq Gold
enzyme, followed by 40 cycles of 95°C for 15 seconds and
60°C for 1 minute.
Every sample was tested in triplicate. Two control samples
were used in each plate to monitor variation between plates,
which was found to be smaller than 5% in our study. The
threshold cycle (Ct) was determined as 0.1 on the basis of the
amplification linear area of both the IGFBP3  and  β-actin
genes. The normalized quantity of IGFBP3 was calculated as
2-ΔCt, where ΔCt was obtained directly by subtracting Ct for
the target gene from Ct for the β-actin gene. The final result
was expressed as 2-ΔCt × 1,000.
The initial samples (batch 1) included in the current analysis
were tumor tissues from 142 patients with primary breast can-
cer and 96 patients with BBD. Also included in the study were
paired adjacent normal tissues from 63 patients with cancer
and 60 patients with BBD. For survival analysis, we analyzed
tumor tissue samples from an additional 379 patients with
breast cancer (batch 2) to enhance statistical power.
Statistical analysis
The data were skewed to the high value; log-transformed
IGFBP3 expression levels were used therefore for analyses.
Linear regression models were used to compare differences in
IGFBP3 expression between comparison groups with adjust-
ment for age (continuous variable) and menopausal status.
The paired t test was used for comparing IGFBP3 expression
levels between tumor tissues and their adjacent normal tis-
sues. To evaluate associations of IGFBP3 expression withAvailable online http://breast-cancer-research.com/content/9/1/R2
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breast cancer survival, patients were grouped on the basis of
batch-specific tertile distribution of the IGFBP3 expression
levels separately for each batch and then merged by tertile cat-
egory. The log-rank test was applied to examine the differ-
ences in survival across the comparison groups. Cox
proportional hazard models were applied for calculating haz-
ard ratios, using the lowest tertile as a reference group after
adjustment for age, TNM (tumor, node, metastasis) stage,
chemotherapy, radiotherapy, and tamoxifen use. All p values
presented are two-sided. SAS software was used for statisti-
cal analysis (version 9.1; SAS Institute, Cary, NC, USA).
Results
The distributions of demographic characteristics and known
breast cancer risk factors of 142 patients with breast cancer
and 96 patients with BBD are shown in Table 1. The mean age
was 48.1 years for patients with breast cancer and 42.7 years
for patients with BBD (p < 0.001). Patients with breast cancer
were more likely to be in their menopause than patients with
BBD (p  < 0.001). Patients with breast cancer showed a
higher waist-to-hip ratio (p = 0.027) than patients with BBD.
The distributions of other breast cancer risk factors were sim-
ilar in patients with cancer and in those with BBD.
Figure 1 shows the distribution of gene expression in tumor tis-
sues by patient groups. Table 2 presents median and inter-
quartile ranges for the expression levels of the IGFBP3 gene
in the tumor tissue and adjacent normal tissue of patients with
breast cancer or BBD. The expression levels of IGFBP3
mRNA were substantially lower in tumor tissues from patients
with cancer than those from patients with BBD (p < 0.001). In
the adjacent normal tissues, however, IGFBP3 expression lev-
els were somewhat higher in patients with cancer than in
patients with BBD, although the difference was not statistically
significant. Among patients with BBD, IGFBP3 expression in
both tumor and adjacent tissues was higher in patients who
had proliferative tumors than those who had non-proliferative
tumors. Among patients with cancer, the gene expression lev-
els in both tumor and adjacent normal tissues were elevated in
advanced stage cancer; however, the difference was not sta-
tistically significant. The expression levels in cancer tissues did
not differ by estrogen receptor (ER) or progesterone receptor
status. Table 3 presents the study result by menopausal sta-
tus. No apparent modifying effect by menopausal status was
found. The difference in IGFBP3 mRNA level by BBD histol-
ogy groups was not statistically significant in postmenopausal
women, perhaps as a result of a small sample size.
IGFBP3 expression in tumor tissues was significantly higher
than that in their paired adjacent normal tissue among patients
with BBD (Table 4; p = 0.006). In contrast, in patients with
breast cancer, IGFBP3 expression levels in the tumor were
lower than the adjacent normal tissue, although the difference
was not statistically significant.
Table 5 shows the association of IGFBP3 expression levels in
cancer tissue with breast cancer survival. The median follow-
up time for patients with breast cancer was about 7 years.
TNM stage was an important prognostic factor. There were no
apparent associations of IGFBP3  expression with overall
Table 1
Demographic and selected breast cancer risk factors for patients with breast cancer and with BBD
Characteristicsa Breast cancer (n = 142) BBD (n = 96) p
Demographic factors
Age (years) 48.1 ± 7.4 42.7 ± 6.7 <0.001
High school education or higher (%) 45.1 49.0 0.555
Known risk factors
Age at menarche 14.6 ± 1.7 14.7 ± 1.7 0.740
Postmenopause (%) 35.5 7.4 <0.001
Age at menopauseb 48.7 ± 4.3 44.6 ± 7.9 0.222
Breast cancer history among first-degree relatives (%) 4.2 3.1 0.662
Ever used hormone replacement therapy (%) 3.5 1.0 0.231
Body mass index (kg/m2) 23.9 ± 3.0 23.3 ± 3.4 0.193
Waist-to-hip ratio 0.81 ± 0.05 0.79 ± 0.05 0.027
Ever consumed alcohol (%) 2.8 2.1 0.723
Physically active during past 10 years (%) 19.0 12.5 0.183
BBD, benign breast disease. a Values are presented in means ± Standard Deviation (unless otherwise noted). bAmong postmenopausal women.Breast Cancer Research    Vol 9 No 1    Ren et al.
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Figure 1
IGFBP3 expression in tumor tissues IGFBP3 expression in tumor tissues. Results are shown for differences between benign breast disease (BBD) and cancer (a) and between grades 
for BBD and stages for cancer (b). Values of p were calculated with a linear regression model including adjustment for age and menopausal status. 
Ct, threshold cycle; IGFBP3, gene encoding insulin-like growth factor binding protein 3.Available online http://breast-cancer-research.com/content/9/1/R2
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survival or disease-free survival. The exclusion of stage IV
patients did not change the results. Stratified analyses by men-
opausal status also yielded similar results for all subjects (data
not shown). Additional analyses were performed to include
IGFBP3 mRNA level (log-transformed) as a continuous varia-
ble in the Cox regression model after additional adjustment for
the batch effect. Again, no apparent association was found
(data not shown).
Discussion
Most studies on the association between IGFBP-3 and breast
cancer risk have been focused on the level of circulating
IGFBP-3 [5]. It has been suggested that IGFBP-3 may also
have an IGF-independent growth inhibitory effect on breast
cancer cells [16,17], and it is important to evaluate tumor tis-
sue specific expressions of IGFBP3 level to understand the
role of this protein in breast tumorigenesis. Few studies have
compared the expression level of the IGFBP3 gene in breast
cancer tissues with those in adjacent normal tissues or the
expression levels across groups of patients with different diag-
noses of breast diseases. Pekonen and colleagues [10]
reported that mRNA levels of IGFBP3 and other IGFBPs were
significantly higher in five breast cancer tissues than in adja-
cent normal tissues as measured by Western blotting. How-
ever, Nardon and colleagues [9] did not find a significant
difference in IGFBP-3 expression between breast tissues from
15 patients with diabetes without breast cancer and breast
tumor tissues from 19 patients with breast cancer by using
immunohistochemistry. We found that IGFBP3 mRNA levels
were substantially lower in cancer tissues than in tumor tis-
sues from patients with BBD. In patients with BBD, IGFBP3
mRNA levels were elevated in tumor tissues, particularly from
patients with a proliferative BBD, compared with adjacent nor-
mal tissues.
Table 2
IGFBP3 mRNA levels for patients with breast cancer and with BBD
Parameter Tumor tissue Adjacent tissue
No. of patients IGFBP3 mRNA level No. of patients IGFBP3 mRNA level
BBD 96 248.1 (152.2, 496.5) 60 178.9 (104.0, 322.7)
Breast cancer 142 132.3 (89.3, 235.2) 63 205.6 (157.1, 301.5)
pa <0.001 0.763
BBD
Non-proliferative lesions 57 185.4 (109.6, 314.2) 34 157.4 (100.2, 243.2)
Proliferative lesions 39 367.0 (217.2, 771.3) 26 218.1 (137.6, 394.3)
pa 0.002 0.044
Breast cancer (by stage)
0 and I 32 125.9 (103.0, 173.2) 21 214.9 (106.4, 262.6)
IIa 63 135.7 (89.6, 268.5) 27 205.6 (158.9, 362.9)
IIb, III and IV 47 141.1 (73.7, 328.9) 15 199.4 (164.4, 320.7)
p for trend testa 0.924 0.448
Breast cancer (by ER 
status)
Positive 75 133.0 (89.3, 230.6) 33 208.1 (165.1, 301.5)
Negative 36 136.0 (77.6, 237.3) 19 192.1 (155.2, 277.1)
Unknown 31 125.8 (90.3, 359.0) 11 214.9 (145.4, 742.1)
pa 0.873 0.376
Breast cancer (by PR 
status)
Positive 74 131.3 (89.3, 230.6) 34 208.2 (167.1, 301.5)
Negative 36 136.3 (77.6, 209.4) 17 169.4 (155.2, 274.6)
Unknown 32 136.0 (90.8, 355.4) 12 193.5 (125.9, 534.7)
pa 0.710 0.472
Results for IGFBP3 mRNA levels are shown as median (25th, 75th centile). BBD, benign breast disease; ER, estrogen receptor, IGFBP3, gene 
encoding insulin-like growth factor binding protein 3; PR, progesterone receptor. aAdjusted for age and menopausal status.Breast Cancer Research    Vol 9 No 1    Ren et al.
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Although no other study has systematically evaluated IGFBP3
expression as in our study, results from a study of prostate
tumor provide some support to our finding. Tennant and col-
leagues [18] compared the expression of IGFBP-3 in prostate
tissue containing benign epithelium, high-grade prostate
intraepithelial neoplasia (PIN), and adenocarcinoma. They
reported a significantly increased IGFBP-3 immunoreactivity in
PIN regions compared with normal epithelium, and a signifi-
cant decrease in malignant cells. However, IGFBP3 mRNA
levels remained virtually unchanged in benign epithelium, PIN,
and adenocarcinoma cells, indicating a pre-translational and/
or post-translational modification of IGFBP-3 [18]. Breast can-
cer cells secrete various types of IGFBP, and the expression
of IGFBP-3 is hormonally regulated [16]. The reduced expres-
sion of IGFBP3 in cancer tissues is consistent with the role of
IGFBP-3 in cancer inhibitory effects. The elevated expression
of IGFBP3 in proliferative benign breast tumor is unexpected.
However, it has been suggested that both transcriptional and
post-transcriptional regulation are involved for the regulation of
IGFBP-3 expression [1,19]. Moreover, various growth factors
Table 3
IGFBP3 mRNA levels for patients with breast cancer and with BBD, stratified by menopausal status
Status Disease Tumor tissue Adjacent tissue
No. of patients IGFBP3 mRNA level No. of patients IGFBP3 mRNA level
Premenopausal BBD 88 231.6 (147.8, 488.0) 54 178.9 (104.6, 300.3)
Breast cancer 91 146.2 (85.2, 289.2) 41 199.4 (156.6, 274.1)
pa <0.001 0.472
BBD
Non-proliferative 
lesions
53 185.4 (109.6, 279.4) 31 139.2 (100.2, 243.2)
Proliferative 
lesions
35 353.1 (197.9, 709.3) 23 219.1 (141.8, 394.3)
pa 0.006 0.055
Breast cancer (by 
stage)
0 and I 23 125.0 (102.7, 169.0) 16 203.1 (85.4, 263.9)
IIa 36 196.5 (86.7, 337.6) 16 200.9 (126.8, 344.1)
IIb, III & IV 32 139.1 (78.9, 301.8) 9 199.4 (165.1, 235.0)
p for trend testa 0.775 0.740
Postmenopausal BBD 7 314.2 (183.9, 528.5) 5 201.8 (73.9, 390.0)
Breast cancer 50 121.8 (96.3, 223.2) 21 208.2 (167.1, 362.8)
pa 0.006 0.184
BBD
Non-proliferative 
lesions
4 249.1 (119.4, 421.3) 3 201.8 (29.5, 390.0)
Proliferative 
lesions
3 472.6 (274.5, 
1500.8)
2 239.5 (73.9, 405.1)
pa 0.157 0.763
Breast cancer (by 
stage)
0 and I 9 126.7 (116.8, 220.8) 5 221.0 (155.2, 262.6)
IIa 26 112.1 (96.3, 202.2) 10 206.9 (179.0, 382.1)
IIb, III & IV 15 141.1 (72.7, 351.8) 6 243.9 (159.0, 727.6)
p for trend testa 0.670 0.308
Results for IGFBP3 mRNA levels are shown as median (25th, 75th centile). BBD, benign breast disease; IGFBP3, gene encoding insulin-like 
growth factor binding protein 3. aAdjusted for age.Available online http://breast-cancer-research.com/content/9/1/R2
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are also involved in the expression of IGFBP-3 [16,20,21]. The
role of IGFBP-3 expression in breast tumors should therefore
be understood in the context of complex regulation for cancer
cell growth.
The level of IGFBP3 mRNA was found to be higher in ER-neg-
ative than in ER-positive tumors in one [22] of the two studies
[10,22] conducted previously. We failed to find this associa-
tion in our study with a larger sample size. In contrast, studies
measuring IGFBP-3 protein levels in a series of human breast
cancer tissues showed higher IGFBP-3 levels in ER-negative
than in ER-positive tumors [11,23-26]. It seems that the asso-
ciation observed might depend on the method used to detect
IGFBP-3 level in breast tissue [2].
Several [10,11,22-25,27,28] but not all [10,26] previous stud-
Table 4
Comparison of IGFBP3 mRNA between tumor tissues and tumor-adjacent tissues
Patient group Number of pairs IGFBP3 mRNA expression level pa
Tumor tissue Adjacent tissue
Benign breast disease 60 240.7 (152.1, 533.5) 178.9 (104.0, 322.7) 0.006
Breast cancer 63 165.1 (103.4, 289.2) 205.6 (157.1, 301.5) 0.246
Results for IGFBP3 mRNA levels are shown as median (25th, 75th centile). IGFBP3, gene encoding insulin-like growth factor binding protein 3. 
ap from paired t test.
Table 5
Association between IGFBP3 mRNA expression and breast cancer survival
Characteristic n Overall survival Disease-free survival
No. of events HR (95% CI) No. of events HR (95% CI)
Age at diagnosis
28–39 years 68 16 1.0 (reference) 21 1.0 (reference)
40–49 years 264 48 0.8 (0.4–1.3) 59 0.7 (0.4–1.1)
50–59 years 136 37 1.2 (0.6–2.1) 44 1.0 (0.6–1.7)
60–64 years 53 10 0.7 (0.3–1.6) 12 0.7 (0.3–1.4)
TNM stage
0, I 124 8 1.0 (reference) 13 1.0 (reference)
IIa 208 39 2.6 (1.3–5.2) 51 2.4 (1.3–4.2)
IIb 132 35 3.9 (1.9–7.8) 39 2.8 (1.6–5.1)
III, IV 49 27 9.8 (4.7–20.3) 31 8.5 (4.6–15.7)
IGFBP3 (all 
subjects)a
T1 173 37 1.0 (reference) 44 1.0 (reference)
T2 174 43 1.2 (0.7–1.8) 55 1.3 (0.9–2.0)
T3 174 31 0.9 (0.5–1.4) 37 0.9 (0.6–1.4)
p for trend 0.596 0.715
IGFBP3 (excluding 
stage IV cases)a
T1 172 37 1.0 (reference) 44 1.0 (reference)
T2 171 42 1.1 (0.7–1.9) 53 1.2 (0.8–1.9)
T3 170 30 0.9 (0.5–1.4) 37 0.9 (0.6–1.4)
p for trend 0.591 0.777
CI, confidence interval; HR, hazard ratio; IGFBP3, gene encoding insulin-like growth factor binding protein 3; TNM, tumor, node, metastasis. 
aAdjusted for age, stages, chemotherapy, radiotherapy, and tamoxifen use.Breast Cancer Research    Vol 9 No 1    Ren et al.
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ies have shown that a high tissue level of IGFBP-3 is related
to unfavorable prognostic factors of breast cancer, such as
large tumor size, elevated S-phase fraction, elevated DNA ane-
uploidy, and low levels of ER or progesterone receptor. High
expression of IGFBP3 was directly associated with poor over-
all survival in one study [26] but not in another [23], and it was
not associated with the recurrence of breast cancer [23,26].
We did not find that IGFBP3 expression was associated with
breast cancer survival in our study, which is consistent with
one of only two previous studies. However, most studies
included only a small number of subjects, ranging between 8
and 200 tumor samples from patients with breast cancer.
Moreover, none of the studies have directly evaluated the
association between IGFBP3 mRNA expression and breast
cancer survival. Our finding therefore needs to be confirmed in
other large studies.
IGFBP-3 acts as a direct growth inhibitor and induces apop-
tosis by an IGF-independent mechanism. It has been shown
that IGFBP-3 inhibits the growth of the IGF-unresponsive
Hs578 human breast cancer cell line [8,16] and enhances the
effects of ceramide and paclitaxol-induced apoptosis directly
[7,29]. In the prostate cancer cell line PC-3, the addition of
exogenous IGFBP-3 resulted in a dose-dependent increase in
the apoptotic index, which was only partly attenuated by the
addition of IGF-I [30]. By contrast, IGFBP-3 was also shown
to have a potential mitogenic effect by enhancing epidermal
growth factor signaling, phosphorylation of the epidermal
growth factor receptor, and the Ras-p44/42 and p38 mitogen-
activated protein kinase (MAPK) signaling pathways [20,31].
The decreased IGFBP3 expression observed in our study of
cancer tissues is consistent with these cancer-inhibitory
effects of IGFBP-3.
We also evaluated gene expression patterns of other IGF sys-
tem components, including IGF-I and IGF-1 receptor (IGF1R)
in our study [32]. Patients with BBD had a significantly higher
IGF-I gene expression than patients with breast cancer in both
tumor and adjacent non-neoplastic tissues. Interestingly, the
expression levels of IGF-I and IGFIR in cancer patients were
substantially higher in tumor-adjacent tissues than in tumor tis-
sues. Patients with a high expression of IGF-I in cancer tissues
showed more favorable overall and disease-free survival [32].
In summary, we found that cancer tissues from patients with
breast cancer had significantly lower IGFBP3 expression than
tumor tissues from patients with BBD, and IGFBP3 expres-
sion in both tumor and adjacent normal tissues were higher in
tissues from patients with proliferative BBD than in those from
patients with non-proliferative BBD. Our findings increase our
understanding of the mechanisms of IGFBP-3 in the patho-
genesis of breast cancer and suggest the need for further
molecular genetic studies to elucidate the biological signifi-
cance of the abnormal expression of IGFBP3 in breast lesions.
Conclusion
IGFBP3  gene expression was systematically evaluated in
tumor tissue and adjacent normal tissues from patients diag-
nosed with breast cancer or BBD. The expression level of
IGFBP3 was higher in tumor tissues from BBDs than in those
from cancer. However, IGFBP3 expression was not associ-
ated with breast cancer survival.
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